Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Influvac 2008/2009
NCT00665509Phase 3Completed
- Sponsor
- Solvay
- Start
- Jun 2008
- Primary completion
- Jul 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of subunit inactivated influenza vaccine in influenza, sponsored by Solvay. Primary endpoints: Hemagglutination Inhibition Titers at 3 weeks, Reactogenicity at 3 weeks and 1 more. Started Jun 2008; status: completed.
02
Drugs
subunit inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00665509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665509.